Novartis (Symbol: NVS) has been named to the Dividend Channel ”International S.A.F.E. 10” list, signifying an international stock with above-average ”DividendRank”statistics including a strong 3.2% yield, as well as a superb track record of at least five years of dividend growth, according to the most recent ”DividendRank” report.
According to the ETF Finder at ETF Channel , Novartis is an underlying holding representing 1.45% of the Powershares International Dividend Achievers ETF ( PID ), which holds $12,345,394 worth of NVS shares. Novartis (Symbol: NVS) made the “Dividend Channel International S.A.F.E. 10” list because of these qualities: S . Solid return – hefty yield and strong DividendRank characteristics; A. Accelerating amount – consistent dividend increases over time; F . Flawless five year history – never a missed or lowered dividend; E. Enduring – at least a half-decade of dividend payments.
The annualized dividend paid by Novartis is $2.75/share, currently paid in annual installments, and its most recent dividend ex-date was on 03/01/2017.
NVS operates in the Drugs & Pharmaceuticals sector, among companies like Johnson & Johnson ( JNJ), and Pfizer Inc ( PFE ).
Source: Nasdaq
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.